In another setback for Eli Lilly, FDA follows EMA in calling for a halt to new Lartruvo prescriptions
A week after Eli Lilly reported the confirmatory study for its cancer drug Lartruvo had failed to help patients live longer, the FDA is discouraging new patients from getting started on the medicine and urging those already on it to consult with their doctors.
The recommendations comes on the heels of a similar announcement from the EMA.
Lartruvo first won an accelerated approval at the FDA in 2016 as part of a combo with the chemotherapy doxorubicin. It was to be a first-line treatment for a subset of patients with soft tissue sarcoma, which had seen no new approvals in decades. By the third quarter of 2018, Lilly had raked in $221.2 million in Lartruvo sales last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.